Supplementary Table and Supplementary Figures 1 through 6 from Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

Supplemental Table 1. Clinical and pathologic characteristics of patients included in tissue microarrays Supplementary Figure 1. B7-H4 expression is low in human and mouse lung cancer cell lines in vitro Supplementary Figure 2. B7-H1 expression does not change with MAPK or proliferation inhibition Supplementary Figure 3. Scoring of PD-L1 and pS6 staining in lung adenocarcinoma and squamous cell carcinoma TMAs Supplementary Figure 4. Co-expression of pS6 and PD-L1 staining in TMAs Supplemental Figure 5. The combination of rapamycin and anti-PD-1 antibody decreases KRAS-driven lung tumor growth Supplementary Figure 6. The combination of rapamycin and αPD-1 blockade decreases NNK-derived syngeneic lung tumor growth.